PCSK9 and atherosclerosis: The therapeutic inhibition of PCSK9 through monoclonal antibodies or siRNA has proven effective in reducing LDL-C levels and the incidence of atherosclerosis, highlighting its potential as a target for treating hypercholesterolemia and possibly other liver-related pathologies [5, 33].